Geode Capital Management
AVIR icon

Geode Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Geode Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.11M Buy
1,958,435
+210,729
+12% +$1.05M ﹤0.01% 2605
2026
Q1 		$9.41M Sell
1,747,706
-93,295
-5% -$428K ﹤0.01% 2417
2025
Q4 		$6.57M Sell
1,841,001
-58,736
-3% -$187K ﹤0.01% 2621
2025
Q3 		$5.51M Sell
1,899,737
-25,836
-1% -$88.2K ﹤0.01% 2734
2025
Q2 		$6.93M Sell
1,925,573
-51,764
-3% -$154K ﹤0.01% 2561
2025
Q1 		$5.91M Buy
1,977,337
+60,551
+3% +$189K ﹤0.01% 2582
2024
Q4 		$6.42M Sell
1,916,786
-7,987
-0.4% -$26.5K ﹤0.01% 2622
2024
Q3 		$6.45M Sell
1,924,773
-85,030
-4% -$308K ﹤0.01% 2626
2024
Q2 		$6.65M Buy
2,009,803
+127,323
+7% +$475K ﹤0.01% 2577
2024
Q1 		$7.61M Buy
1,882,480
+74,568
+4% +$292K ﹤0.01% 2489
2023
Q4 		$5.51M Buy
1,807,912
+82,183
+5% +$249K ﹤0.01% 2651
2023
Q3 		$5.18M Buy
1,725,729
+80,691
+5% +$275K ﹤0.01% 2619
2023
Q2 		$6.15M Buy
1,645,038
+154,974
+10% +$580K ﹤0.01% 2580
2023
Q1 		$4.99M Buy
1,490,064
+52,705
+4% +$214K ﹤0.01% 2626
2022
Q4 		$6.91M Buy
1,437,359
+48,156
+3% +$244K ﹤0.01% 2481
2022
Q3 		$7.9M Buy
1,389,203
+227,779
+20% +$1.74M ﹤0.01% 2404
2022
Q2 		$8.25M Buy
1,161,424
+132,664
+13% +$906K ﹤0.01% 2386
2022
Q1 		$7.43M Sell
1,028,760
-52,033
-5% -$353K ﹤0.01% 2554
2021
Q4 		$9.66M Buy
1,080,793
+48,197
+5% +$751K ﹤0.01% 2464
2021
Q3 		$36.2M Buy
1,032,596
+355,543
+53% +$9.86M ﹤0.01% 1544
2021
Q2 		$14.5M Buy
677,053
+402,168
+146% +$12.1M ﹤0.01% 2198
2021
Q1 		$17M Buy
274,885
+7,019
+3% +$474K ﹤0.01% 1982
2020
Q4 		$11.2M Buy
+267,866
New +$8.63M ﹤0.01% 2094

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management's AVIR Position: Q2 2026 in Review

Geode Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 12% in Q2 2026, buying an estimated $1.05M and bringing the position to 1,958,435 shares worth $9.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Geode Capital Management first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $36.2M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Geode Capital Management held 1,958,435 shares of Atea Pharmaceuticals worth $9.11M as of Q2 2026.
  • Geode Capital Management bought 210,729 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Atea Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2605 holding.
  • Geode Capital Management first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Atea Pharmaceuticals position peaked at $36.2M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.